Selected article for: "antigenic drift and human infection"

Author: Crowe, James E.
Title: Recent Advances in the Study of Human Antibody Responses to Influenza Virus Using Optimized Human Hybridoma Approaches
  • Cord-id: kcm86l15
  • Document date: 2009_12_1
  • ID: kcm86l15
    Snippet: Influenza viruses exhibit a fascinating level of antigenic heterogeneity that facilitates re-infection in the human population. The human antibody repertoire also manifests endless capability for variation in the genes that specify the portion of antibody molecules interacting with epitopes. A recent explosion of techniques for isolating human monoclonal antibodies to viruses has led to isolation of new antibodies that allow glimpses into the molecular basis for recognition and escape that under
    Document: Influenza viruses exhibit a fascinating level of antigenic heterogeneity that facilitates re-infection in the human population. The human antibody repertoire also manifests endless capability for variation in the genes that specify the portion of antibody molecules interacting with epitopes. A recent explosion of techniques for isolating human monoclonal antibodies to viruses has led to isolation of new antibodies that allow glimpses into the molecular basis for recognition and escape that underlies the constant antigenic drift in influenza surface proteins. These studies also reveal evidence for lifelong persistence of immunity to some influenza viruses.

    Search related documents:
    Co phrase search for related documents
    • acute virus and low affinity: 1
    • acute virus and low efficiency: 1
    • acute virus and low frequency: 1
    • acute virus and lymphoid tissue: 1, 2
    • acute virus and mab antibody: 1, 2, 3, 4, 5
    • acute virus and mabs generation: 1
    • acute virus and mabs potential: 1, 2
    • low affinity and mab antibody: 1, 2, 3
    • low affinity and mab therapeutic: 1, 2
    • low affinity and mabs potential: 1
    • low efficiency and lymphoid tissue: 1
    • lymphoid tissue and mabs generation: 1
    • mab antibody and mabs generation: 1, 2, 3, 4, 5
    • mab antibody and mabs monoclonal antibody: 1, 2, 3, 4
    • mab antibody and mabs potential: 1, 2, 3, 4, 5, 6
    • mab therapeutic and mabs generation: 1
    • mab therapeutic and mabs monoclonal antibody: 1
    • mab therapeutic and mabs potential: 1, 2